Open AccessA rare case of primary choriocarcinoma in the sigmoid colon
Author(s) -
Hiromitsu Maehira,
Tomoharu Shimizu,
Hiromichi Sonoda,
Eiji Mekata,
Tomoharo Yamaguchi,
Tohru Miyake,
Mitsuaki Ishida,
Tohru Tani
Publication year - 2013
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v19.i39.6683
Subject(s) - choriocarcinoma , medicine , colorectal cancer , sigmoid colon , adenocarcinoma , bevacizumab , regimen , gastroenterology , oncology , rectum , chemotherapy , pathology , cancer
Primary colorectal choriocarcinoma is an extremely rare neoplasm and is usually associated with a poor prognosis. Only 13 cases of colorectal choriocarcinoma have previously been reported. There is no standard chemotherapeutic regimen for this tumor type. A 68-year-old man presented with melena and was diagnosed with sigmoid colonic adenocarcinoma with multiple liver metastases. He underwent a laparoscopic sigmoidectomy. Pathology revealed choriocarcinoma with a focal component of moderately differentiated adenocarcinoma of colon origin. Based on the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) results, mFOLFOX6 and bevacizumab were administered, which suppressed aggressive tumor growth for 4 mo. The patient died 9 mo after the initial diagnosis. Our study results suggest that the standard chemotherapy regimen for colorectal cancer might have suppressive effects against primary colorectal choriocarcinoma. Moreover, CD-DST may provide, at least in part, therapeutic insight for the selection of appropriate antitumor agents for such patients.